197 related articles for article (PubMed ID: 20859636)
1. Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram.
Papakostas GI; Larsen K
Eur Arch Psychiatry Clin Neurosci; 2011 Apr; 261(3):147-56. PubMed ID: 20859636
[TBL] [Abstract][Full Text] [Related]
2. Effects of escitalopram on sleep problems in patients with major depression or generalized anxiety disorder.
Stein DJ; Lopez AG
Adv Ther; 2011 Nov; 28(11):1021-37. PubMed ID: 22057726
[TBL] [Abstract][Full Text] [Related]
3. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.
Lepola U; Wade A; Andersen HF
Int Clin Psychopharmacol; 2004 May; 19(3):149-55. PubMed ID: 15107657
[TBL] [Abstract][Full Text] [Related]
4. Escitalopram in the treatment of major depressive disorder: a meta-analysis.
Kennedy SH; Andersen HF; Thase ME
Curr Med Res Opin; 2009 Jan; 25(1):161-75. PubMed ID: 19210149
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
6. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
Favré P
Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
[TBL] [Abstract][Full Text] [Related]
7. Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder.
Kasper S; Ebert B; Larsen K; Tonnoir B
Int J Neuropsychopharmacol; 2012 Jul; 15(6):715-25. PubMed ID: 22008735
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
[TBL] [Abstract][Full Text] [Related]
9. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
Bech P; Lönn SL; Overø KF
J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
[TBL] [Abstract][Full Text] [Related]
10. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study.
Ou JJ; Xun GL; Wu RR; Li LH; Fang MS; Zhang HG; Xie SP; Shi JG; Du B; Yuan XQ; Zhao JP
Psychopharmacology (Berl); 2011 Feb; 213(2-3):639-46. PubMed ID: 20340011
[TBL] [Abstract][Full Text] [Related]
12. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
[TBL] [Abstract][Full Text] [Related]
13. Escitalopram in the treatment of adolescent depression: a randomized, double-blind, placebo-controlled extension trial.
Findling RL; Robb A; Bose A
J Child Adolesc Psychopharmacol; 2013 Sep; 23(7):468-80. PubMed ID: 24041408
[TBL] [Abstract][Full Text] [Related]
14. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder.
Moore N; Verdoux H; Fantino B
Int Clin Psychopharmacol; 2005 May; 20(3):131-7. PubMed ID: 15812262
[TBL] [Abstract][Full Text] [Related]
15. Citalopram and escitalopram in the treatment of major depressive disorder: a pooled analysis of 3 clinical trials.
Li H; Li T; Li G; Luo J
Ann Clin Psychiatry; 2014 Nov; 26(4):281-7. PubMed ID: 25401715
[TBL] [Abstract][Full Text] [Related]
16. Escitalopram in the treatment of anxiety symptoms associated with depression.
Bandelow B; Andersen HF; Dolberg OT
Depress Anxiety; 2007; 24(1):53-61. PubMed ID: 16937393
[TBL] [Abstract][Full Text] [Related]
17. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
Wade AG; Schlaepfer TE; Andersen HF; Kilts CD
J Psychiatr Res; 2009 Feb; 43(5):568-75. PubMed ID: 18954875
[TBL] [Abstract][Full Text] [Related]
18. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
Chokka P; Legault M
Depress Anxiety; 2008; 25(12):E173-81. PubMed ID: 19006260
[TBL] [Abstract][Full Text] [Related]
19. Baseline severity of depression predicts antidepressant drug response relative to escitalopram.
Kilts CD; Wade AG; Andersen HF; Schlaepfer TE
Expert Opin Pharmacother; 2009 Apr; 10(6):927-36. PubMed ID: 19317630
[TBL] [Abstract][Full Text] [Related]
20. Qualitative changes in symptomatology as an effect of treatment with escitalopram in generalized anxiety disorder and major depressive disorder.
Lecrubier Y; Dolberg OT; Andersen HF; Weiller E
Eur Arch Psychiatry Clin Neurosci; 2008 Apr; 258(3):171-8. PubMed ID: 18084791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
